Omeprazolo Sos (Omeprazole Sodium)

Omeprazolo Sos is a proton pump inhibitor that acts on the gastric acid secretion pathway. It is indicated for several acid‑related conditions:

• Gastroesophageal reflux disease (GERD): alleviates heartburn and promotes healing of esophageal erosion.
• Peptic ulcer disease: supports ulcer healing and reduces recurrence risk.
• Zollinger‑Ellison syndrome: controls excessive gastric acid production.
• Erosive esophagitis: aids the healing of erosive damage in the esophagus.
• NSAID‑induced ulcer prophylaxis: lowers the risk of ulcer formation in patients taking non‑steroidal anti‑inflammatory drugs.
• Helicobacter pylori eradication regimens: used as part of combination therapy to improve eradication rates.

• Omeprazole sodium is a reversible covalent inhibitor of the gastric H+/K+‑ATPase enzyme (the proton pump) located in the parietal cells of the stomach. By binding to the pump's cysteine residues, it blocks the final step of acid secretion, leading to a sustained increase in gastric pH and reduced acidity in the gastrointestinal tract.

Omeprazolo Sos may cause a range of adverse reactions. Most are mild and resolve after discontinuation.

Common Side Effects

• Headache: mild, transient headache reported by some patients.
• Diarrhea: loose stools occurring during treatment.
• Nausea: occasional feeling of queasiness.
• Abdominal pain: mild stomach discomfort.
• Flatulence: increased gas production.
• Constipation: reduced bowel movements.

Serious or Rare Side Effects

• Clostridioides difficile infection: severe colitis associated with antibiotic‑related dysbiosis.
• Acute interstitial nephritis: kidney inflammation presenting with rash, fever, and impaired renal function.
• Osteoporosis‑related fractures: increased risk of hip, wrist or vertebral fractures with long‑term use.
• Hypomagnesemia: low serum magnesium levels causing muscle cramps or cardiac arrhythmia.
• Stevens‑Johnson syndrome: rare severe skin reaction with blistering and mucosal involvement.
• Anaphylaxis: immediate hypersensitivity reaction with airway compromise.

Before prescribing Omeprazolo Sos, clinicians should consider several safety aspects.

• Assess renal and hepatic function: adjust use in severe impairment.
• Review concomitant medications: potential for drug‑drug interactions.
• Monitor long‑term users: watch for bone density loss and magnesium levels.
• Use the lowest effective dose: limit duration to the shortest period needed.
• Pregnancy and lactation: evaluate risk‑benefit ratio.
• Store at below 25°C: keep in the original container, protect from moisture and light.

Omeprazolo Sos can affect the absorption and metabolism of several medicines. Clinicians should evaluate these interactions carefully.

Major Interactions (Avoid)

• Ketoconazole and itraconazole: reduced antifungal efficacy due to decreased gastric acidity.
• Atazanavir: markedly lowered plasma concentrations, compromising HIV treatment.
• Clopidogrel: diminished antiplatelet effect, increasing cardiovascular risk.

Moderate Interactions (Monitor Closely)

• Warfarin: potential increase in INR, requiring more frequent monitoring.
• Digoxin: higher serum levels may occur, necessitating dose adjustment.
• Methotrexate: reduced clearance can raise toxicity risk.
• Phenytoin: altered metabolism may affect seizure control.